3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Conditions
Esophageal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
44
Fluorouracil
16
Cisplatin
15
Oxaliplatin
13
Capecitabine
11
Paclitaxel
10
lenvatinib
8
Leucovorin
8
Irinotecan
6
Docetaxel
6
trifluridine tipiracil drug combination
3
regorafenib
3
Saline Solution
3
Levoleucovorin
3
Gemcitabine
3
Bevacizumab
3
patritumab deruxtecan
2
Trastuzumab
2
S 1 (combination)
2
Radiotherapy
2
Cetuximab
2
Carboplatin
2
zanidatamab
1
vicriviroc
1
tremelimumab
1
tislelizumab
1
tipiracil
1
spartalizumab
1
sinoporphyrin sodium
1
ribociclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
patritumab deruxtecan
×
Gastrointestinal
×
Clear all
NCT06469944
2026-05-26
MK-3475-06C
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
160 enrolled
NCT06445972
2026-05-12
MK-3475-06D
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
210 enrolled